News about "Cancer Treatment"

Boehringer Ingelheim, SBP Group Sign USD 7.36 Billion Oncology Deal

Boehringer Ingelheim and China's SBP Group have entered into a multi-programme oncology agreement covering six pre-clinical programmes based on ADC and T-cell engager technologies, with potential milestone payments of up to USD 7 billion.

Cancer Treatment | 05/11/2026 | By News Bureau |  103

ORIC and Cancer Research UK Advance CIP2A Cancer Therapy

ORIC Pharmaceuticals has announced agreement with Cancer Research UK to advance a potential first-in-class CIP2A-targeted therapy into clinical development.

Cancer Treatment | 07/10/2026 | By News Bureau |  280

Layered Nanoparticle Platform Could Expand Targeted Radioisotope Cancer Therapies

Scientists have developed a specialised nanoplatelet that rapidly captures and strongly retains radioisotopes, potentially creating a versatile platform for targeted cancer imaging, radionuclide therapy and theranostic applications.

Cancer Treatment | 19/08/2026 | By News Bureau |  147

Innovent and Daiichi Sankyo Partner for Vanflyta Commercialisation in China

Innovent Biologics and Daiichi Sankyo have entered an exclusive agreement to commercialise Vanflyta in China, expanding access for FLT3-ITD positive AML patients.

Cancer Treatment | 11/08/2026 | By News Bureau |  133

UK MHRA Approves Retifanlimab for Merkel Cell Skin Cancer

The UK MHRA has approved retifanlimab (ZYNYZ) for the treatment of advanced Merkel Cell Carcinoma (MCC), a rare and aggressive skin cancer with significant unmet medical need.

Cancer Treatment | 08/07/2026 | By Akanki |  151

US FDA Approves Pfizer's Ibrance for Maintenance Treatment of HR+, HER2+ Metastatic Breast Cancer

FDA approval makes Ibrance the first CDK4/6 inhibitor indicated for HR+ metastatic breast cancer regardless of HER2 status.

Cancer Treatment | 26/06/2026 | By News Bureau |  301

US FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each with Trodelvy

The US Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with Trodelvy as first-line treatment for adults with PD-L1-positive (CPS ≥10) advanced Triple-Negative Breast Cancer (TNBC).

Cancer Treatment | 26/06/2026 | By News Bureau |  255

Novartis Reports Strong Long-Term Efficacy of Scemblix in Chronic Myeloid Leukemia Trial

Novartis’ Scemblix demonstrated sustained efficacy and a favourable safety profile over nearly three years of follow-up, reinforcing its potential as a frontline treatment option for adults with Philadelphia chromosome-positive chronic myeloid leukemia.

Cancer Treatment | 03/06/2026 | By News Bureau |  240

Onco-Innovations Subsidiary Partners with GSK on Real-World Oncology Data Research

Inka Health and GSK will collaborate to develop real-world data methodologies aimed at improving the applicability of oncology clinical trial findings across diverse patient populations and healthcare settings.

Cancer Treatment | 07/05/2026 | By News Bureau |  182

Merck Completes USD 5.8 Billion Acquisition of Terns Pharmaceuticals to Strengthen Oncology Pipeline

Merck acquires Terns Pharmaceuticals, advancing development of next-generation therapies for chronic myeloid leukaemia.

Cancer Treatment | 06/05/2026 | By News Bureau |  195